RTSN — Retension Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $127.06m
- $141.74m
Annual cashflow statement for Retension Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2024 December 31st | 2025 December 31st | |
|---|---|---|
| Period Length: | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS |
| Standards: | USG | USG |
| Status: | Final | Final |
| Net Income/Starting Line | -1.91 | -6.3 |
| Non-Cash Items | 0.126 | 0.245 |
| Other Non-Cash Items | ||
| Changes in Working Capital | 0.029 | -1.72 |
| Change in Prepaid Expenses | ||
| Change in Accounts Payable | ||
| Change in Accrued Expenses | ||
| Change in Other Liabilities | ||
| Cash from Operating Activities | -1.76 | -7.78 |
| Financing Cash Flow Items | 3.61 | 18.5 |
| Other Financing Cash Flow | ||
| Cash from Financing Activities | 3.61 | 18.5 |
| Beginning Cash Balance | ||
| Ending Cash Balance | ||
| Net Change in Cash | 1.86 | 10.7 |